Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: Latanoprost; Ophthalmic Solutions; Pharmaceutical Solutions; Travoprost

Criteria

Inclusion Criteria:

• 18 years or older.

• Diagnosis of open-angle glaucoma or ocular hypertension in at least one eye.

• Intraocular pressure (IOP) controlled with BAK (benzalkonium chloride) preserved IOP-lowering medication for 1 year, with last 6 months on XALATAN® monotherapy.

• Best corrected visual acuity of -0.6 logMAR or better in each eye.

• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Treatment with BAK preserved artificial tears within 30 days of Visit 1.

• Known or suspected Sjogren's disease.

• Uncontrolled IOP.

• History or evidence of infectious or inflammatory ocular conditions.

• Progressive retinal or optic nerve disease.

• Ocular laser surgery within 3 months of Visit 1.

• Keratorefractive ocular laser procedures, corneal surgery or surgery to the corneal surface within 1 year of Visit 1.

• Current use of punctal plugs or punctal cautery.

• Use of systemic medications that has not been stable for 30 days prior to Visit 1.

• Use of contact lens within 30 days of Visit 1.

• Other protocol-defined exclusion criteria may apply.